Uterine cancer is one of the gynecologic cancers. Gynecologic cancers arise in the tissues or organs of the female reproductive tract.
The specific gynecologic cancer type is generally named after the organ where it originates. Each year, approximately 80,000 women are diagnosed with one of these types with a majority of gynecologic cancers classified as either ovarian or uterine.
Uterine cancer usually develops in the lining of the uterus (known as the endometrium) and if it continues to grow, it moves into the muscle. The uterus (or womb) is the pelvic organ where the fetus normally develops. The most common type of uterine cancer is endometrial and usually doesn’t occur until menopause.
A more rare type forms in the connective tissue, which supports the uterus and is called uterine sarcoma.
Currently, oncologists base their treatment strategies upon the stage of disease. Early stage may be managed with surgery alone. For more advanced stages, physicians generally use standard chemotherapy protocols.
Uterine cancer patients typically receive carboplatin plus Taxol, or Cytoxan plus Adriamycin, either alone or in combination with radiation.
Nagourney Cancer Institute uses each patient's tumor to determine the right drug or drugs to prescribe for a woman with a gynecologic cancer. Our clinical staff works with each patient to provide an individualized and comprehensive treatment plan.